Log in
OTCMKTS:QTXB

Quantrx Biomedical Stock Forecast, Price & News

$0.0055
0.00 (0.00 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.00
MA: $0.01
$0.01
52-Week Range
$0.00
Now: $0.01
$0.01
VolumeN/A
Average Volume130,120 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta0.52
QuantRx Biomedical Corporation engages in the development and commercialization patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market, based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infections, urinary incontinences, general catamenial uses, and other medical needs. It also provides InSync, a feminine hygienic interlabial padand; Unique miniform, which is available as a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad, for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. The company was incorporated in 1986 and is based in Tualatin, Oregon.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:QTXB
CUSIPN/A
CIKN/A
Phone212-980-2235

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.02) per share

Profitability

Net Income$-620,000.00

Miscellaneous

EmployeesN/A
Next Earnings Date11/13/2020 (Estimated)
OptionableNot Optionable
$0.0055
0.00 (0.00 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTXB News and Ratings via Email

Sign-up to receive the latest news and ratings for QTXB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quantrx Biomedical (OTCMKTS:QTXB) Frequently Asked Questions

How has Quantrx Biomedical's stock price been impacted by Coronavirus?

Quantrx Biomedical's stock was trading at $0.0046 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QTXB shares have increased by 19.6% and is now trading at $0.0055.
View which stocks have been most impacted by COVID-19
.

When is Quantrx Biomedical's next earnings date?

Quantrx Biomedical is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Quantrx Biomedical
.

Who are some of Quantrx Biomedical's key competitors?

What other stocks do shareholders of Quantrx Biomedical own?

Who are Quantrx Biomedical's key executives?

Quantrx Biomedical's management team includes the following people:
  • Dr. Shalom Z. Hirschman, Chairman, CEO & Principal Accounting Officer (Age 83)

What is Quantrx Biomedical's stock symbol?

Quantrx Biomedical trades on the OTCMKTS under the ticker symbol "QTXB."

How do I buy shares of Quantrx Biomedical?

Shares of QTXB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quantrx Biomedical's stock price today?

One share of QTXB stock can currently be purchased for approximately $0.01.

What is Quantrx Biomedical's official website?

The official website for Quantrx Biomedical is www.quantrx.com.

How can I contact Quantrx Biomedical?

Quantrx Biomedical's mailing address is 10190 SW 90TH AVENUE, TUALATIN OR, 97062. The company can be reached via phone at 212-980-2235.

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.